Myopia

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)

Retrieved on: 
Thursday, September 29, 2022
Inflammation, Safety, IOP, Allergy, MD, FDA, Food, Prevalence, Glaucoma, Frustration, IND, OSD, NDA, Timolol, Myopia, Latanoprost, Patient, Presbyopia, BAK, Eye, Physician, CEO, CLEAR, New Drug Application, Duane syndrome, Solubility, US Foods, GLOBE, R, Brimonidine/timolol, Disease, Generic drug, Pharmaceutical industry

CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial. With these results, TearClear plans to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in the first quarter of 2023. Upon approval, TC-002 will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.

Key Points: 
  • With these results, TearClear plans to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in the first quarter of 2023.
  • Upon approval, TC-002 will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.
  • Many patients on preserved glaucoma medications experience moderate to severe signs and symptoms of ocular surface disease (OSD)1.
  • This causes discomfort for patients, frustration for physicians and drives additional costs for payers, said Stuart Raetzman, CEO of TearClear.

Global Intraocular Lens Market Report to 2031 - Players Include Alcon, Bausch Health, Carl Zeiss Meditech and Hoya - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022
Health, Optical, Diabetes, Adoption, Porter's five forces analysis, Incidence, Sorbitol, Risk, Prevalence, Congenital cataract, National Eye Institute, National Center for Biotechnology Information, Astigmatism, Growth, Partnership, Myopia, Government, Cataract, Patient, Presbyopia, Johnson & Johnson, Eye, NCBI, Approximation error, Severe cognitive impairment, Benchmarking, US, Diabetic retinopathy, Megasphaera, National Center on Education and the Economy, CAGR, Retail, Telescopic sight, Pharmaceutical industry

The intraocular lens market was valued $3,777.16 million in 2021 and is expected to reach $6,535.51 million by 2031, growing at a CAGR of 5.6% from 2022 to 2031.

Key Points: 
  • The intraocular lens market was valued $3,777.16 million in 2021 and is expected to reach $6,535.51 million by 2031, growing at a CAGR of 5.6% from 2022 to 2031.
  • Increase in prevalence of cataract and rise in initiatives taken by government to eliminate avoidable blindness drive the growth of the global intraocular lens market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the intraocular lens market analysis from 2021 to 2031 to identify the prevailing intraocular lens market opportunities.
  • The report includes the analysis of the regional as well as global intraocular lens market trends, key players, market segments, application areas, and market growth strategies.

Johnson & Johnson Vision Expands Access to Myopia Management for More Patients with Abiliti™ Overnight Lenses

Retrieved on: 
Wednesday, September 28, 2022
Center for Epidemiologic Studies Depression Scale, Health, Safety, Child, Dioptre, Twitter, Ophthalmology, FDA, Food, Elective surgery, Lens (anatomy), Social welfare model, Lens, LinkedIn, Disability, Medtech, Johnson & Johnson Vision, Astigmatism, Life, Review, Severe cognitive impairment, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, MS, Eye, Cataract, Balance (ability), Follow, ACUVUE, 7th Sky Entertainment, School, OD, Lion, Optometry, Risk, Pharmaceutical industry, Camera, Hospital, Medical device, Telescopic sight, Facebook, Myopia

"By expanding the parameters for Abiliti Overnight lenses, it creates more opportunities for eye care professionals to reach even more patients," said Chandra Mickles, OD, MS, FAAO, FSLS, North America Professional Education Lead, Myopia, Johnson & Johnson Vision.

Key Points: 
  • "By expanding the parameters for Abiliti Overnight lenses, it creates more opportunities for eye care professionals to reach even more patients," said Chandra Mickles, OD, MS, FAAO, FSLS, North America Professional Education Lead, Myopia, Johnson & Johnson Vision.
  • The lenses are available in two different lens designs: ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management and ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management for Astigmatism.7
    Patients and eye care professionals seeking more information can visit: www.seeyourabiliti.com .
  • ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management are orthokeratology lenses approved by the U.S. Food and Drug Administration (FDA) for myopia management.
  • Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor

Retrieved on: 
Wednesday, September 21, 2022
Retina, Therapy, MAP, COVID-19, FDA, ORA, Ophthalmology, Glaucoma, U.S. Securities and Exchange Commission, KYS, Spillage, Myopia, Forward-looking statement, Patient, Cornea, Presbyopia, MIGS, Mydriasis, Glaucoma surgery, Technology, Public health, Novartis, Board of directors, Leadership, NASDAQ, Board, Congress, Medicine, Marketing, GLOBE, Genentech, Management, Medical device, Pharmaceutical industry, 3D printing, Alcon

At 18, Ianchulev emigrated to the United States from post-communist Bulgaria with only $200 in his pocket.

Key Points: 
  • At 18, Ianchulev emigrated to the United States from post-communist Bulgaria with only $200 in his pocket.
  • Medicine was viewed as a public service rather than a prestigious career choice in his home country.
  • Spending time around his mother and her patients would serve as the inspiration that would motivate Ianchulev to pursue a career in medicine.
  • Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics.

Mark Mandel, MD, is One of the Bay Area's First Ophthalmologists to Use the Revolutionary New EVO Visian® Implantable Contact Lens (ICL)

Retrieved on: 
Thursday, September 8, 2022
Intraocular lens, University, Technology, UCLA School of Dentistry, Ophthalmology, Doctor, David Geffen School of Medicine at UCLA, Solution, San Francisco Bay Area, Glasses, Night vision, Doctor Doctor (American TV series), ICL, EVO, Refraction, Lens, MD, GLOBE, Patient, Myopia, Refractive surgery, FDA, UV, University of Oxford, Lens (anatomy), Cornea, Astigmatism, California Pacific Medical Center, Eye, Mandel, Medical device, Dentistry, Medicine, LASIK

"It is clear to me that EVO Visian ICL provides superior results to previous versions of the implantable contact lenses ," said Mandel.

Key Points: 
  • "It is clear to me that EVO Visian ICL provides superior results to previous versions of the implantable contact lenses ," said Mandel.
  • EVO Visian ICL is an outpatient surgery that is typically completed in under half an hour.
  • Although the EVO ICL is new to the United States, over one million people worldwide have received EVO Visian ICL.
  • To learn more about EVO Visian ICL and overcome nearsightedness, please schedule a consultation at Optima Ophthalmic Medical Associates by emailing [email protected] or calling 877-210-2020, Extension 3.

WIMI Hologram Academy: VR Live Plus Online Education Application Development Status Analysis

Retrieved on: 
Thursday, September 8, 2022
People, STEM, Software, COVID-19, Technology, 3D, Observation, VR, Research, Physics, Cooking, Science, Milwaukee Art Museum, Anatomy, GLOBE, Biology, Confusion, Painting, Student, Risk, Beijing University of Technology, K-12, Travel, Sphinx, University, Mathematics, Education, PPI, Time, Collection, SAT, Communication, Climate change, Industry, Partnership, AP, Giza Plateau, NASDAQ, Bureau of Labor Statistics, Imagination, Orientation, Occupation, School, News, Language, Mother-tongue education in Hong Kong, Cobalt, Virtual reality, Health, AI, Immersion, Lecture, Learning, Chemistry, Myopia, Attention, Knowledge, Computer graphics, Tutoring, Video game console, Tourism, Helen Frankenthaler

The development of VR live streaming under the premise of high-speed development of 5G communication technology also provides strong technical support for better presentation of online education.

Key Points: 
  • The development of VR live streaming under the premise of high-speed development of 5G communication technology also provides strong technical support for better presentation of online education.
  • (NASDAQ: WIMI),have analyzed and researched the specific applications of VR live streaming technology in online education, and discussed the significance and development of VR education.
  • A VR online education in the fall of 2018 is used as an example to specifically analyze the differences and connections between traditional education and VR online education.
  • The most intuitive thing about VR live application in education is that the live content is about education teaching, combining the advantages of virtual reality technology and live streaming in education to give learners a better learning experience.

North America Anti-Blue Ray Myopia Lenses Market to Grow by 7% Yearly Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022
Health, Optical, Digital, Government, Distribution, Retail, Person, Melatonin, Macular degeneration, Computer vision syndrome, Hospital, Myopia, Prevalence, CAGR, Population, AMD, Single, Country, Visual impairment, Growth, Organization, Sleep

By reducing exposure to blue light on a regular basis, anti-blue ray myopia lenses enable melatonin levels to revert to normal.

Key Points: 
  • By reducing exposure to blue light on a regular basis, anti-blue ray myopia lenses enable melatonin levels to revert to normal.
  • The rising prevalence of myopia among young adults and children is another factor that is expected to boost demand for anti-blue ray myopia lenses.
  • Organizations that produce anti-blue ray myopia lenses are also using effective marketing strategies and releasing cutting-edge items to increase their market share.
  • The US market dominated the North America Anti-Blue Ray Myopia Lenses Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $763.9 Million by 2028.

Kubota Vision Announces the Results of Clinical Study in Children Using Wearable Myopia Control Device based on Kubota Glass Technology

Retrieved on: 
Tuesday, September 6, 2022
Optical, Health, Clinical Trials, Medical Devices, Nanotechnology, CEO, Research, View, Ophthalmology, Doctor of Philosophy, OCT, Kubota, Incidence, Publishing, Vision Research, MD, Company, Risk, Â, Trial of the century, Patient, Visual impairment, Pharmaceutical industry, Myopia

Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the results from a clinical study in children using a wearable myopia control device based on Kubota Glass technology.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the results from a clinical study in children using a wearable myopia control device based on Kubota Glass technology.
  • We will continue accumulating evidence for Kubota Glass technology as a safe, effective and easy approach to control myopia.
  • Kubota Pharmaceutical groups pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Eyenovia to Participate in Multiple Medical Meetings in September

Retrieved on: 
Tuesday, September 6, 2022
Mydriasis, Forward-looking statement, COVID-19, U.S. Securities and Exchange Commission, Technology, GLOBE, Presbyopia, Marketing, Therapy, NASDAQ, Myopia, Pharmaceutical industry, Risk management

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP) therapeutics, today announced that the company will be participating in multiple medical meetings in September.

Key Points: 
  • NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP) therapeutics, today announced that the company will be participating in multiple medical meetings in September.
  • Details of the presentations are as follows:
    Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics.
  • Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression.
  • Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements.

Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Children

Retrieved on: 
Thursday, September 1, 2022
Cataract, Myopia, Safety, Life, Severe cognitive impairment, Trial of the century, Doctor of Philosophy, Glasses, Glaucoma, Hope, Phase, Approximation error, Science, MD, GLOBE, Atropine, Prevalence, Company, FDA, Population, Risk, Lens (anatomy), CHAMP, Eye, Cover My Eyes (Pain and Heaven), First Ever, Patient, Pharmaceutical industry

The CHAMP study has been designed, in collaboration with FDA, to evaluate whether NVK002 eye drops are safe and effective as a treatment for the progression of myopia in children.

Key Points: 
  • The CHAMP study has been designed, in collaboration with FDA, to evaluate whether NVK002 eye drops are safe and effective as a treatment for the progression of myopia in children.
  • With this milestone, Vyluma remains on track for primary analysis readout later this year and regulatory submission in 2023.
  • NVK002 is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.
  • Vylumas pipeline of therapies is led by NVK002, an investigational, preservative-free, low-dose atropine eye drop to treat the progression of myopia in children.